Baird raised the firm’s price target on Quest Diagnostics (DGX) to $191 from $190 and keeps an Outperform rating on the shares. The firm updated its model following its Investor Day.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics: Stable Long-Term Growth Prospects and Strategic Market Positioning
- Quest Diagnostics Unveils Growth Strategy at Investor Day
- Autodesk in proxy fight, General Mills reports mixed Q3: Morning Buzz
- Quest Diagnostics Outlines Growth Strategies at Investor Day
- Quest Diagnostics reaffirms FY25 adjusted EPS view $9.55-$9.80, consensus $9.71